3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Glioblastoma
3
Brain Neoplasms
2
Neoplasms
1
Gliosarcoma
1
Interventions
Temozolomide
53
Bevacizumab
45
Radiotherapy
28
Radiosurgery
21
Carboplatin
14
Erlotinib Hydrochloride
11
Radiation
10
pembrolizumab
9
Magnetic Resonance Spectroscopy
9
Etoposide
9
Vorinostat
8
Trastuzumab
8
Irinotecan
8
Sunitinib
7
Sorafenib
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Lapatinib
7
Capecitabine
7
dabrafenib
6
Ipilimumab
6
Imatinib Mesylate
6
Cyclophosphamide
6
Sirolimus
5
Hydroxyurea
5
Everolimus
5
Bortezomib
5
temsirolimus
4
cabozantinib
4
binimetinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Brain Neoplasms
×
depatuxizumab mafodotin
×
Clear all
NCT02573324
2023-05-11
Intellance1
AbbVie
Phase 3
Completed
691 enrolled
28 charts
NCT02343406
2020-05-22
INTELLANCE-2
AbbVie
Phase 2
Completed
266 enrolled
23 charts